HUNG-CHIH YANGJIA-HORNG KAO2021-07-122021-07-1220161936-0533https://www.scopus.com/inward/record.uri?eid=2-s2.0-84955178733&doi=10.1007%2fs12072-015-9698-x&partnerID=40&md5=c38a14c512ea285a914557eef96d2038https://scholars.lib.ntu.edu.tw/handle/123456789/570870[SDGs]SDG3alanine aminotransferase; biological marker; hepatitis B core antibody; hepatitis B core antigen; hepatitis B surface antigen; hepatitis B virus DNA; hepatitis B(e) antigen; unclassified drug; virus DNA; biological marker; hepatitis B antibody; hepatitis B surface antigen; hepatitis B(e) antigen; area under the curve; blood level; chronic hepatitis B; disease course; Editorial; hepatitis; hepatitis B; hepatitis B e antigen negative hepatitis; human; immune clearance; immunological parameters; immunological tolerance; liver cell carcinoma; liver cirrhosis; low replication phase; nonhuman; predictive value; predictor variable; priority journal; receiver operating characteristic; risk; virus reactivation; blood; cross-sectional study; forecasting; genetics; Hepatitis B virus; immunology; isolation and purification; liver tumor; virology; Biomarkers; Carcinoma, Hepatocellular; Cross-Sectional Studies; Forecasting; Hepatitis B Antibodies; Hepatitis B e Antigens; Hepatitis B Surface Antigens; Hepatitis B virus; Hepatitis B, Chronic; Humans; Liver Cirrhosis; Liver Neoplasms; Predictive Value of Tests; RiskEditorial10.1007/s12072-015-9698-x267326892-s2.0-84955178733